for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sanofi SA

SANp.ED

Latest Trade

87.66EUR

Change

1.05(+1.21%)

Volume

18,227

Today's Range

87.38

 - 

88.40

52 Week Range

67.82

 - 

95.80

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
86.61
Open
87.82
Volume
18,227
3M AVG Volume
40.69
Today's High
88.40
Today's Low
87.38
52 Week High
95.80
52 Week Low
67.82
Shares Out (MIL)
1,253.60
Market Cap (MIL)
109,036.50
Forward P/E
14.71
Dividend (Yield %)
3.64

Next Event

Sanofi SA at JPMorgan CEO Talk

Latest Developments

More

Sanofi Announces Acquisition Of Principia Biopharma Inc.

Sanofi Says CHMP Recommends Approval Of Supemtek For Prevention Of Influenza In Adults Aged 18 Years And Older

BRIEF-Sanofi, GSK Sign Agreements With Canada For Up To 72 Million Doses Of Adjuvanted COVID-19 Vaccine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Industry

Biotechnology & Drugs

Contact Info

54 rue la Boetie

75008

France

+33.1.53774000

https://www.sanofi.com/

Executive Leadership

Serge Weinberg

Independent Chairman of the Board

Paul Hudson

Chief Executive Officer, Member of the Executive Committee, Director

Jean-Baptiste Chasseloup de Chatillon

Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Karen Linehan

Executive Vice President - Legal Affairs and General Counsel, Member of the Executive Committee

Caroline Luscombe

Executive Vice President of Human Resources, Member of the Executive Committee

Key Stats

2.00 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

35.1K

2018

34.5K

2019

36.1K

2020(E)

37.2K
EPS (EUR)

2017

5.540

2018

5.470

2019

5.990

2020(E)

5.887
Price To Earnings (TTM)
9.79
Price To Sales (TTM)
2.89
Price To Book (MRQ)
1.72
Price To Cash Flow (TTM)
8.66
Total Debt To Equity (MRQ)
39.42
LT Debt To Equity (MRQ)
33.77
Return on Investment (TTM)
11.36
Return on Equity (TTM)
9.44

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up